Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
Proteasome
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN17237 | VR23 | 1624602-30-7 | VR23 is a small molecule inhibitor which targets 2 of the 20S proteasome with IC50 of 1 nM and can induce apoptosis of cancer cells via cyclin Emediated centrosome amplification |
| CSN22527 | TY-51469 | 603987-59-3 | TY-51469 is a chymase inhibitor with IC50s for simian and human chymases of 0.4 and 7.0 nM, respectively. |
| CSN18857 | TIR-199 | 1514925-83-7 | TIR-199 a natural product-derived syrbactin structural analog which covalently binds each of the three catalytic subunits 1 2 and 5 and revealed key interaction sites and is used for the treatment of multiple myeloma and other forms of cancer |
| CSN22501 | Rpn11-IN-1 | 2084867-65-0 | Rpn11-IN-1 is a potent and selective inhibitor of proteasome subunit Rpn11 with an IC50 of 390 nM |
| CSN22188 | Proteasome-IN-1 | 374080-21-4 | Proteasome-IN-1 is a proteasome inhibitor extracted from patent WO 2013142376 A1 |
| CSN15914 | PI-1840 | 1401223-22-0 | PI-1840 is a potent and selective inhibitor for chymotrypsin-like CT-L IC50 value 27 014 nM over trypsin-like and peptidylglutamyl peptide hydrolyzing IC50 values 100 M activities of the proteasome |
| CSN18603 | Oprozomib | 935888-69-0 | ONX 0912 is an inhibitor of proteasome that targets the chymotrypsin-like activity of the 20S proteasome subunits 5 (IC50 36 nM) and LMP7 (IC50 82 nM). |
| CSN17316 | MLN9708 | 1201902-80-8 | MLN9708 is the prodrug of MLN2238 which is an inhibitor of the chymotrypsin-like proteolytic 5 site of the 20S proteasome with IC50 and Ki of 34 nM 093 nM respectively |
| CSN11436 | MG-132 | 133407-82-6 | MG-132 is an inhibitor of proteasome IC50 100 nM and calpain IC50 12 nM |
| CSN19716 | Marizomib | 437742-34-2 | Marizomib, a natural product isolated and purified from marine bacteria Salinispora tropica and Salinispora arenicola, inhibits 20S proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. |
| CSN12950 | Ixazomib | 1072833-77-2 | Ixazomib selectively inhibits the chymotrypsin-like proteolytic 5 site of 20S proteasome with IC50 and Ki of 34 nM and 093 nM respectively |
| CSN17356 | Ixazomib Citrate | 1239908-20-3 | Ixazomib citrate is the citrate form of ixazomib which is an inhibitor of chymotrypsin-like proteolytic (5) site of the 20S proteasome with IC50 of 3.4 nM. |
| CSN19673 | GNF-6702 | 1799329-72-8 | GNF-6702 is a proteasome inhibition for treatment of leishmaniasis Chagas disease and sleeping sickness |
| CSN15770 | Epoxomicin | 134381-21-8 | Epoxomicin is a potent anti-tumor agent isolated from Actinomycetes that is used as a selective and irreversible inhibitor of the 20S proteasome. |
| CSN12951 | Delanzomib | 847499-27-8 | Delanzomib is an orally active inhibitor of the chymotrypsin-like activity of proteasome with IC50 of 38 nM with only marginal inhibition of the tryptic and peptidylglutamyl activities of the proteosome |
| CSN22376 | Clasto-Lactacystin β-lactone | 154226-60-5 | Clasto-Lactacystin -lactone, a natural active metabolite of lactacystin, which is a metabolite of Streptomyces, acts as an irreversible 20S proteasome inhibitor. |
| CSN13893 | Carfilzomib | 868540-17-4 | Carfilzomib is an irreversible proteasome inhibitor with IC50 of 5 nM and can treat relapsed and refractory multiple myeloma |
| CSN19285 | Capzimin | 2084868-04-0 | Capzimin shows 5-fold selectivity for Rpn11 over the related JAMM proteases and 2 logs selectivity over several other metalloenzymes |
| CSN10115 | Bortezomib | 179324-69-7 | Bortezomib is an inhibitor of 20S proteasome with Ki of 0.6 nM. |
| CSN22676 | AM 114 | 856849-35-9 | |
| CSN22831 | Gliotoxin | 67-99-2 | |
| CSN15835 | ONX-0914 | 960374-59-8 |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
